Loading...

RIGL RIGEL PHARMACEUTICALS INC Expansion Plans 8-K Filing

RGL

RGL

RIGEL PHARMACEUTICALS INC

(RIGL)

2024 8-K

Show Summary

Show Summary

Equity Offerings

Financial Statements

Patent Settlement

Board Appointment

Financial Results

Financial Results

Clinical Trial Update

Q3 Financial Results

Director Resignation

Collaboration Agreement

Financial Results Announcement

Reverse Stock Split

Reverse Stock Split

Approval of 2018 Equity Inc...

Financial Results

Amendment to Credit and Sec...

Financial Results Announcement

Asset Purchase Agreement

Financial Results

Financial Results

Financial Results

Equity Incentive Plan Amend...

Financial Results

Financial Results Announcement

Resignation of Chief Medica...

Financial Results

External Links:

Rigel Pharmaceuticals entered into a collaboration and license agreement with Kissei Pharmaceutical, granting Kissei exclusive rights to develop and commercialize olutasidenib in Japan, Korea, and Taiwan, with Rigel receiving an upfront payment of $1

AI Assistant

RIGEL PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.